Panacos Pharmaceuticals 8-K 2007
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Amendment No. 1
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 25, 2006
PANACOS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
134 Coolidge Avenue
Watertown, Massachusetts 02472
(Address of principal executive offices and zip code)
Registrants telephone number, including area code: (617) 926-1551
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
(a) Not applicable.
(b) Not applicable.
(c) Not applicable.
(d) On a Current Report on Form 8-K dated October 27, 2006, Panacos Pharmaceuticals, Inc. (Panacos or the Company) announced that Laurent Fischer, M.D. was appointed as a director of the Company on October 25, 2006. By this reference, the contents of that Current Report are incorporated herein. On February 21, 2007, Dr. Fischer was appointed to the Nominating and Governance Committee of the Board of Directors.
(e) Not applicable.
(f) Not applicable.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.